

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listing of claims.

**Listing of Claims:**

1-20. (canceled)

21. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding amino acid residues 1 to 574 of SEQ ID NO:6;

(b) a nucleotide sequence encoding amino acid residues 2 to 574 of SEQ ID NO:6;

(c) a nucleotide sequence encoding amino acid residues 25 to 574 of SEQ ID NO:6;

(d) a nucleotide sequence encoding amino acid residues 1 to 388 of SEQ ID NO:8; and

(e) a nucleotide sequence that is the complement of (a), (b), (c), or (d).

22. (previously presented) The nucleic acid molecule of claim 21 comprising a nucleotide sequence according to (a).

23. (previously presented) The nucleic acid molecule of claim 21 comprising a nucleotide sequence according to (b).

24. (previously presented) The nucleic acid molecule of claim 21 comprising a nucleotide sequence according to (c).

25. (previously presented) The nucleic acid molecule of claim 21 comprising a nucleotide sequence according to (d).

26. (previously presented) The nucleic acid molecule of claim 21 comprising a nucleotide sequence according to (e).

27. (previously presented) The nucleic acid molecule of claim 22 comprising nucleotides 130 to 1851 of SEQ ID NO:5.

28. (previously presented) The nucleic acid molecule of claim 22 comprising nucleotides 3 to 1166 of SEQ ID NO:7.

29. (currently amended) The nucleic acid molecule of claim 21 ~~comprising a nucleotide sequence heterologous to SEQ ID NO:5 wherein the nucleotide sequence is fused to a heterologous polynucleotide sequence.~~

30. (currently amended) The nucleic acid molecule of claim 29, wherein said heterologous polynucleotide sequence encodes a polypeptide heterologous to SEQ ID NO:6.

31. (previously presented) The nucleic acid molecule of claim 30, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

32. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 21.

33. (previously presented) The recombinant vector of claim 32, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

34. (previously presented) A recombinant host cell comprising the vector of claim 32.

35. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 21 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

36. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 21, comprising:

- (a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and
- (b) recovering said polypeptide from the culture.

37. (currently amended) A composition comprising the nucleic acid molecule of claim 21 and a **pharmaceutically acceptable** carrier.

38. (currently amended) An isolated nucleic acid molecule encoding a first amino acid sequence at least 95% identical to the entire length of a second amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence encoding amino acid residues 1 to 574 ~~or of~~ SEQ ID NO:6;
- (b) a nucleotide sequence encoding amino acid residues 2 to 574 of SEQ ID NO:6;
- (c) an amino acid sequence encoding amino acid residues 25 to 574 of SEQ ID NO:6; and
- (d) an amino acid sequence encoding amino acid residues 1 to 388 of SEQ ID NO:8;

wherein % identity is determined using the BESTFIT computer program, and wherein said nucleic acid molecule encodes a polypeptide that binds FK506.

39. (previously presented) The nucleic acid molecule of claim 38 that encodes an amino acid sequence at least 95% identical to a second amino acid sequence according to (a).

40. (previously presented) The nucleic acid molecule of claim 38 that encodes an amino acid sequence at least 95% identical to a amino acid sequence according to (b).

41. (previously presented) The nucleic acid molecule of claim 38 that encodes an amino acid sequence at least 95% identical to a second amino acid sequence according to (c).

42. (previously presented) The nucleic acid molecule of claim 38 that encodes an amino acid sequence at least 95% identical to a second amino acid sequence according to (d).

43. (currently amended) The nucleic acid molecule of claim 41 ~~that comprises a nucleotide sequence heterologous to SEQ ID NO:5 wherein the nucleic acid molecule is fused to a heterologous polynucleotide sequence.~~

44. (currently amended) The nucleic acid molecule of claim 43, wherein said heterologous polynucleotide sequence encodes a polypeptide heterologous to SEQ ID NO:6.

45. (previously presented) The nucleic acid molecule of claim 44, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

46. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 41.

47. (previously presented) The recombinant vector of claim 46, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

48. (previously presented) A recombinant host cell comprising the vector of claim 46.

49. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 41 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

50. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 41, comprising:

- (a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and
- (b) recovering said polypeptide from the culture.

51. (currently amended) A composition comprising the nucleic acid molecule of claim 41 and a **pharmaceutically acceptable** carrier.

52. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding the full-length polypeptide encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193;
- (b) a nucleotide sequence encoding the full-length polypeptide, lacking the N-terminal methionine, which is encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193;
- (c) a nucleotide sequence encoding the secreted portion of the polypeptide encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193; and
- (d) a nucleotide sequence that is the complement of (a), (b), or (c).

53. (previously presented) The nucleic acid molecule of claim 52 comprising a nucleotide sequence according to (a).

54. (previously presented) The nucleic acid molecule of claim 52 comprising a nucleotide sequence according to (b).

55. (previously presented) The nucleic acid molecule of claim 52 comprising a nucleotide sequence according to (c).

56. (previously presented) The nucleic acid molecule of claim 52 comprising a nucleotide sequence according to (d).

57. (canceled)

58. (previously presented) The nucleic acid molecule of claim 52 comprising the nucleotide sequence of the cDNA, as contained in clone HSYBM46, that encodes the secreted form of the polypeptide encoded by clone HSYBM46, which clone was deposited with the ATCC as accession number 209193.

59. (currently amended) The nucleic acid molecule of claim 52 ~~comprising a~~ wherein the nucleotide sequence is fused to a polynucleotide sequence heterologous to the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193.

60. (currently amended) The nucleic acid molecule of claim 59, wherein said heterologous polynucleotide sequence encodes a polypeptide heterologous to the polypeptide encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193.

61. (previously presented) The nucleic acid molecule of claim 60, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

62. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 52.

63. (previously presented) The recombinant vector of claim 62, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

64. (previously presented) A recombinant host cell comprising the vector of claim 52.

65. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 52 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

66. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 52, comprising:

- (a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and
- (b) recovering said polypeptide from the culture.

67. (currently amended) A composition comprising the nucleic acid molecule of claim 52 and a **pharmaceutically acceptable** carrier.

68. (previously presented) An isolated nucleic acid molecule encoding a first amino acid sequence at least 95% identical to the entire length of a second amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193,
- (b) the amino acid sequence of the full-length polypeptide, lacking the N-terminal methionine, which is encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193; and
- (c) the amino acid sequence of the secreted portion of the polypeptide encoded by the cDNA contained in clone HSYBM46 deposited with the ATCC as accession number 209193;

wherein % identity is determined using BESTFIT computer program, and wherein said nucleic acid molecule encodes a polypeptide that binds FK506.

69. (previously presented) The nucleic acid molecule of claim 68 encoding an amino acid sequence at least 95% identical to a second amino acid sequence according to (a).

70. (previously presented) The nucleic acid molecule of claim 68 encoding an amino acid sequence at least 95% identical to a second amino acid sequence according to (b).

71. (previously presented) The nucleic acid molecule of claim 68 encoding an amino acid sequence at least 95% identical to a second amino acid sequence according to (c).

72. (currently amended) The nucleic acid molecule of claim 71 ~~that comprises wherein said nucleic acid molecule is fused to a polynucleotide sequence heterologous to~~ the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193.

73. (currently amended) The nucleic acid molecule of claim 72, wherein said heterologous polynucleotide sequence encodes a polypeptide heterologous to the polypeptide encoded by the cDNA contained in clone HSYBM46 as deposited with the ATCC as accession number 209193.

74. (previously presented) The nucleic acid molecule of claim 73, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

75. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 71.

76. (previously presented) The recombinant vector of claim 75, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

77. (previously presented) A recombinant host cell comprising the vector of claim 75.

78. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 71 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

79. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 71, comprising:

(a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and  
(b) recovering said polypeptide from the culture.

80. (currently amended) A composition comprising the nucleic acid molecule of claim 71 and a pharmaceutically acceptable carrier.

81. (previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193; and

(b) a nucleotide sequence that is the complement of (a).

82. (previously presented) The nucleic acid molecule of claim 81 comprising a nucleotide sequence according to (a).

83. (previously presented) The nucleic acid molecule of claim 81 comprising a nucleotide sequence according to (b).

84. (previously presented) The nucleic acid molecule of claim 82 comprising the nucleotide sequence of the cDNA, as contained in clone HFKBC47, that encodes the polypeptide encoded by clone HFKBC47, which clone was deposited with the ATCC as accession number 209193.

85. (currently amended) The nucleic acid molecule of claim 81 ~~comprising a~~ wherein the nucleotide sequence is fused to a polynucleotide sequence heterologous to the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193.

86. (currently amended) The nucleic acid molecule of claim 84-85, wherein said heterologous polynucleotide sequence encodes a polypeptide heterologous to the

polypeptide encoded by the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193.

87. (previously presented) The nucleic acid molecule of claim 86, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

88. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 81.

89. (previously presented) The recombinant vector of claim 88, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

90. (previously presented) A recombinant host cell comprising the vector of claim 88.

91. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 81 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

92. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 81, comprising:

(a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and  
(b) recovering said polypeptide from the culture.

93. (previously presented) A composition comprising the nucleic acid molecule of claim 81 and a pharmaceutically acceptable carrier.

94. (previously presented) An isolated nucleic acid molecule encoding a first amino acid sequence at least 95% identical to the entire length of an amino acid sequence of the polypeptide encoded by the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193, wherein % identity is determined using the

BESTFIT computer program, and wherein said nucleic acid molecule encodes a polypeptide that binds FK506.

95. (currently amended) The nucleic acid molecule of claim 94 ~~that comprises wherein said nucleic acid molecule is fused to a polynucleotide sequence heterologous to~~ the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193.

96. (currently amended) The nucleic acid molecule of claim 95, wherein said heterologous ~~polynucleotide~~ sequence encodes a polypeptide heterologous to the polypeptide encoded by the cDNA contained in clone HFKBC47 as deposited with the ATCC as accession number 209193.

97. (previously presented) The nucleic acid molecule of claim 96, wherein said heterologous polypeptide is an Fc domain of immunoglobulin.

98. (previously presented) A recombinant vector comprising the nucleic acid molecule of claim 94.

99. (previously presented) The recombinant vector of claim 98, wherein the nucleic acid molecule is operably associated with a regulatory element that controls expression of said nucleic acid molecule.

100. (previously presented) A recombinant host cell comprising the vector of claim 98.

101. (previously presented) A recombinant host cell comprising the nucleic acid molecule of claim 94 operably associated with a regulatory element that controls expression of said nucleic acid molecule.

102. (previously presented) A method of producing a polypeptide encoded by the nucleic acid molecule of claim 94, comprising:

- (a) culturing a host cell comprising said nucleic acid molecule under conditions suitable to produce said polypeptide; and
- (b) recovering said polypeptide from the culture.

103. (currently amended) A composition comprising the nucleic acid molecule of claim 94 and a ~~pharmaceutically acceptable~~ carrier.